4 Other than being on GLP-1s, higher risk patients include: those in the dose-escalation phase and those with upper GI symptoms (eg, nausea, vomiting, dyspepsia, abdominal distension, and abdominal discomfort/pain). 4 And obviously, other high-risk group includes patients with comorbidities associated with delayed gastric emptying (eg, poorly controlled diabetes, Parkinsons disease, bowel dysmotility) as well as those on other drugs that slow gastric emptying (eg, opioids, tricyclic antidepressants, marijuana, alcohol)
Bone Health: - Bone Density: There's an interest in understanding how GLP-1 receptor agonists might impact bone health, with some studies suggesting potential benefits in bone density, though this remains an area of ongoing research
Although the relationship between GLP-1RAs and thyroid cancer risk remains uncertain, caution is advised when prescribing GLP-1RAs in individuals with a history of thyroid cancer or in those with higher risk [24]
Not copy-paste scripts
Probleme gastrointestinale grea, vrsturi, crampe abdominale, diaree
GLP-1 receptor agonists mimic the endogenous incretin hormone GLP-1, exerting multiple physiological effects that contribute to metabolic improvement
